KYMERA THERAPEUTICS INC. - COMMON STOCK

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

11 Aug 2025 04:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025

04 Aug 2025 04:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

26 Jun 2025 20:56:15 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Proposed Public Offering

25 Jun 2025 13:05:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

25 Jun 2025 04:05:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

02 Jun 2025 04:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

30 May 2025 13:01:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

29 May 2025 04:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference

19 May 2025 09:15:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

09 May 2025 04:01:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

09 May 2025 04:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

07 May 2025 04:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

24 Apr 2025 04:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

22 Apr 2025 03:59:59 By Nasdaq GlobeNewswire

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

09 Apr 2025 04:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

27 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

26 Feb 2025 04:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

20 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

30 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

14 Jan 2025 04:00:00 By Nasdaq GlobeNewswire